tradingkey.logo
tradingkey.logo
Search

Fortress Biotech Inc

FBIO
Add to Watchlist
3.130USD
-0.160-4.86%
Close 07-31 16:00ETQuotes delayed by 15 min
103.87MMarket Cap
0.81P/E TTM

Fortress Biotech Inc

3.130
-0.160-4.86%
View Detailed Chart
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-4.86%

5 Days

-6.29%

1 Month

+1.29%

6 Months

+0.97%

Year to Date

-14.48%

1 Year

+72.93%

Key Figures
3.280Open
3.280High
643.00KVolume
0.81P/E TTM
4.92P/E Dynamic
--Dividend TTM
1.94%Turnover Ratio
3.290Prev. Close
3.080Low
1.50MTurnover
LossP/E Static
0.64P/B
0.00%Div Yield TTM
48.21%ROA
4.53052wk High
1.43Volume Ratio
-55.89MNet Profit
33.19MShares
3.8490EPS TTM
1.22Beta
129.25%ROE
1.70052wk Low
6.07%Amplitude
54.21%Gross Margin
103.87MMarket Cap
2.72Reward/Risk
4.24%Risk Rate

TradingKey Stock Score of Fortress Biotech Inc

Currency: USD Updated: 2026-07-31

Key Insights

Fortress Biotech Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 63 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.00.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Fortress Biotech Inc's Score

Industry at a Glance

Industry Ranking
63 / 155
Overall Ranking
136 / 4281
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Fortress Biotech Inc Highlights

StrengthsRisks
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Growing
The company is in a growing phase, with the latest annual income totaling USD 63.26M.
Overvalued
The company’s latest PE is 0.81, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 6.02M shares, decreasing 12.64% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.

Analyst Rating

Based on 2 analysts
Buy
Current Rating
11.000
Target Price
+228.36%
Upside Space

Fortress Biotech Inc News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 2 analysts
Buy
Current Rating
11.000
Target Price
+228.36%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Fortress Biotech Inc
FBIO
2
Amgen Inc
AMGN
37
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
34
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32

Indicators

Indicators
Sell(3)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.094
Neutral
RSI(14)
45.941
Neutral
STOCH(KDJ)(9,3,3)
20.125
Sell
ATR(14)
0.236
Low Volatility
CCI(14)
-159.743
Sell
Williams %R
93.446
Oversold
TRIX(12,20)
0.492
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(3)
Neutral(0)
Buy(3)
Indicators
Value
Direction
MA5
3.286
Sell
MA10
3.361
Sell
MA20
3.333
Sell
MA50
3.047
Buy
MA100
2.812
Buy
MA200
2.984
Buy

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Fortress Biotech Inc Info

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Ticker SymbolFBIO
CompanyFortress Biotech Inc
CEORosenwald (Lindsay A)
Websitehttps://www.fortressbiotech.com/

Shareholders

Shareholders
Shareholders
Proportion
Rosenwald (Lindsay A)
13.81%
Weiss (Michael S)
6.85%
Opaleye Management Inc.
3.28%
Vanguard Capital Management, LLC
2.91%
Summit Financial, LLC
1.32%
Other
71.83%

FAQs

What is the current price of Fortress Biotech Inc (FBIO)?

The current price of Fortress Biotech Inc (FBIO) is 3.13.

What is the symbol of Fortress Biotech Inc?

The ticker symbol of Fortress Biotech Inc is FBIO.

What is the 52-week high of Fortress Biotech Inc?

The 52-week high of Fortress Biotech Inc is 4.53.

What is the 52-week low of Fortress Biotech Inc?

The 52-week low of Fortress Biotech Inc is 1.70.

What is the market capitalization of Fortress Biotech Inc?

The market capitalization of Fortress Biotech Inc is 103.87M.

Is Fortress Biotech Inc (FBIO) currently rated as Buy, Hold, or Sell?

According to analysts, Fortress Biotech Inc (FBIO) has an overall rating of Buy, with a price target of 11.00.

What is the Earnings Per Share (EPS TTM) of Fortress Biotech Inc (FBIO)?

The Earnings Per Share (EPS TTM) of Fortress Biotech Inc (FBIO) is -0.07.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.